NCT00193544View on ClinicalTrials.gov

Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 31, 2002

Primary Completion Date

October 31, 2005

Study Completion Date

January 31, 2009

Conditions
Multiple Myeloma
Interventions
DRUG

Arsenic Trioxide

DRUG

Thalidomide

Sponsors

Collaborators (1)

CTI BioPharma
All Listed Sponsors
collaborator

CTI BioPharma

INDUSTRY

lead

SCRI Development Innovations, LLC

OTHER

NCT00193544 - Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter